Dr. Greig received his B.S. from Chelsea College, University of London, in 1978. He received his Ph.D. in pharmacology from the University of London in 1982. Dr. Greig did his postdoctoral training in the NIA, designing and developing drug candidates for cancer and drug abuse, and investigating technology to augment delivery of neuropeptides and antisense into the brain. He left the NIA in 1989 to help initiate Athena Neurosciences, a biotechnology company in San Francisco, California. Dr. Greig returned to the NIA as a Senior Investigator in 1992 and is currently chief of the Drug Design and Development Section. His laboratory's research focuses on the conception, design and development of novel therapeutics for treatment of Alzheimer's disease, other neurodegenerative diseases and type-2 diabetes.